Despite the encouraging efficacy of ICIs in treating BMs, other modalities that can enhance the activity of anti–PD-1/PD-L1 monotherapy are urgently needed, and prospective trials in NSCLC BM patients are warranted. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.